Literature DB >> 21455266

Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.

Oleg Y Dmitriev1.   

Abstract

The Wilson disease protein (ATP7B) is a copper-transporting ATPase that is responsible for regulating copper homeostasis in human tissues. ATP7B is associated with cancer resistance to cisplatin, one of the most widely used anticancer drugs. This minireview discusses the possible mechanisms of tumor resistance to cisplatin mediated by ATP7B. Cisplatin binds to the N-terminal cytosolic domain of ATP7B, which contains multiple copper-binding sites. Active platinum efflux catalyzed by ATP7B is unlikely to significantly contribute to cisplatin resistance in vivo. Transient platinum sequestration in the metal-binding domain followed by transfer to an acceptor protein or a low molecular weight compound is proposed as an alternative mechanism of cisplatin detoxification in the cell.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455266     DOI: 10.1139/o10-150

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  15 in total

1.  The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.

Authors:  Xiang-Ping Li; Ji-Ye Yin; Ying Wang; Hui He; Xi Li; Wei-Jing Gong; Juan Chen; Chen-Yue Qian; Yi Zheng; Fang Li; Tao Yin; Zhi-Cheng Gong; Bo-Ting Zhou; Yu Zhang; Ling Xiao; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Tumour Biol       Date:  2014-05-23

2.  Developing multisite empirical force field models for Pt(II) and cisplatin.

Authors:  John P Cvitkovic; George A Kaminski
Journal:  J Comput Chem       Date:  2016-11-11       Impact factor: 3.376

3.  The metal chaperone Atox1 regulates the activity of the human copper transporter ATP7B by modulating domain dynamics.

Authors:  Corey H Yu; Nan Yang; Jameson Bothe; Marco Tonelli; Sergiy Nokhrin; Natalia V Dolgova; Lelita Braiterman; Svetlana Lutsenko; Oleg Y Dmitriev
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

Review 4.  Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy.

Authors:  Macus Tien Kuo; Siqing Fu; Niramol Savaraj; Helen H W Chen
Journal:  Cancer Res       Date:  2012-09-07       Impact factor: 12.701

5.  Mechanistic basis for overcoming platinum resistance using copper chelating agents.

Authors:  Zheng D Liang; Yan Long; Wen-Bin Tsai; Siqing Fu; Razelle Kurzrock; Mihai Gagea-Iurascu; Fan Zhang; Helen H W Chen; Bryan T Hennessy; Gordon B Mills; Niramol Savaraj; Macus Tien Kuo
Journal:  Mol Cancer Ther       Date:  2012-08-21       Impact factor: 6.261

6.  A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin.

Authors:  Yong Zhang; Qiang Zhang; Zhongze Fan; Jue Sun; Xulin Liu; Lingling Cheng; Ao Li; Jianhua Xu
Journal:  Pathol Oncol Res       Date:  2014-08-08       Impact factor: 3.201

7.  A Role for The ATP7A Copper Transporter in Tumorigenesis and Cisplatin Resistance.

Authors:  Sha Zhu; Vinit Shanbhag; Yanfang Wang; Jaekwon Lee; Michael Petris
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

8.  Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.

Authors:  Avani Vyas; Umamaheswar Duvvuri; Kirill Kiselyov
Journal:  Biochem J       Date:  2019-12-19       Impact factor: 3.857

Review 9.  Ion channels and transporters in the development of drug resistance in cancer cells.

Authors:  Else K Hoffmann; Ian H Lambert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-02-03       Impact factor: 6.237

10.  Organic cation transporter 3 mediates cisplatin and copper cross-resistance in hepatoma cells.

Authors:  Sarah Guttmann; Gursimran Chandhok; Sara Reinartz Groba; Christoph Niemietz; Vanessa Sauer; Amanda Gomes; Giuliano Ciarimboli; Uwe Karst; Andree Zibert; Hartmut H Schmidt
Journal:  Oncotarget       Date:  2017-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.